Search
Inavolisib
go.drugbank.com/drugs/DB15275ApprovedInvestigational[A264563] Newer PI3K inhibitors, like inavolisib, seek to mitigate this attenuation. … [A264563] Chemotherapeutic agents targeting the PI3K p110α catalytic subunit have shown antitumor activity and a manageable safety profile - some of which are in clinical use, like [alpelisib] - but preclinical
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 Enzyme InducersNemtabrutinib
go.drugbank.com/drugs/DB18866Investigationaltrial NCT05624554 (A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK
Synonyms: 1,5-Anhydro-2-[[5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-2,3,4-trideoxy-D-erythro-hexitol, (2-chloro-4-phenoxyphenyl)(4-(((3r,6s)-6-(hydroxymethyl)tetrahydro-2h-pyran-3-yl)amino)-7h-pyrrolo(2,3-d)pyrimidin-5-yl)methanoneLumasiran
go.drugbank.com/drugs/DB15935ApprovedInvestigational[L23554] This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calcium crystal formation. … [L23394] Prior to this approval, therapy consisted of symptomatic treatment such as hyperhydration, inhibitors of crystallization, [pyridoxine], and renal transplant.
Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 Enzyme InhibitorsCIGB 300
go.drugbank.com/drugs/DB16464InvestigationalCIGB-300, is under investigation in clinical trials for its potential to treat various conditions, including NCT01639638 (recurrent and nonrecurrent condyloma) and NCT01639625 (squamous cell carcinoma
Aminopterin
go.drugbank.com/drugs/DB08878ApprovedWithdrawnClinicians need to be aware of the characteristic teratologic effects of aminopterin and methotrexate. … In the 1950's its production was discontinued in favor of methotrexate, which is less potent but less toxic. Off label, aminopterin has also been used in the treatment of psoriasis.
Abiprubart
go.drugbank.com/drugs/DB19333InvestigationalAbiprubart is being evaluated for its efficacy and safety in participants with Sjögren's Disease in clinical trial NCT06531395
Synonyms: Gamma4 heavy chain humanized (1-441) [VH (Homo sapiens IGHV1-3*01 (83.7%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [8.8.7] (26-33.51-58.97-103)) (1-114)-Homo sapiens IGHG4*01, nG4m(a) CH2 L92, G4v5 h P10 (CH1, Immunoglobulin G4-kappa, anti-[Homo sapiens CD40 (TNFRSF5, tumor necrosis factor receptor (TNFR) superfamily member 5, p50)], humanized monoclonal antibodyValoctocogene roxaparvovec
go.drugbank.com/drugs/DB15561ApprovedInvestigationalWithdrawn[L43282] The expression of hFVIII-SQ is driven by a liver-specific promoter, which enables hepatocytes to produce factor VIII protein and increase the levels of active factor VIII in blood. … [L43292] Hemophilia A treatments such as prophylactic regimens of exogenous factor VIII or [emicizumab] improve the clinical outcomes of patients but do not eliminate breakthrough bleeding.
Synonyms: DNA (synthetic adeno-associated virus 5 vector BMN 270 human blood-coagulation factor VIII SQ variant-specifying)Olezarsen
go.drugbank.com/drugs/DB18728ApprovedInvestigational[A264888] Olezarsen works to reduce the plasma triglyceride levels by reducing APOC3 production. … [A264888,A264893] Olezarsen is conjugated to a ligand containing three N-acetyl-galactosamine (GalNAc) residues to enable its delivery to hepatocytes.
Synonyms: DNA, D(P-THIO)((2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))M5RU-(2'-O-(2-METHOXYETHYL))M5RU-M5C-T-T-G-T-M5C-M5C-A-G-M5C-(2'-O-(2-METHOXYETHYL), ALL-P-AMBO-5'-O-(((6-(5-((TRIS(3-(6-(2-ACETAMIDO-2-DEOXY-.BETA.Growth hormone-releasing peptide 1
go.drugbank.com/drugs/DB19259Investigationalinvestigation in clinical trial NCT00381602 (A Phase II, Randomized, Cross-over, Vehicle-controlled, Double-blind, Multicenter Study of the Safety, Pharmacodynamics, and Preliminary Efficacy of GHRP-1/AG
Vibostolimab
go.drugbank.com/drugs/DB16420InvestigationalSubstudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK